Saladax Develops First-Ever Rapid Test for an Antipsychotic Drug Using a Single Drop of Blood to Aid Psychiatrists in the Treatment of Schizophrenia
5.9.2019 16:30:00 EEST | Business Wire | Press release
Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite. The MyCare Insite Clozapine Test is the first and only rapid point-of-care test CE marked to aid mental health professionals in the treatment and monitoring of patients with schizophrenia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005085/en/
The MyCare Insite Clozapine Test delivers accurate and precise clozapine blood levels comparable to laboratory results. Psychiatrists need immediate information to make informed decisions during a patient visit. The MyCare Insite Clozapine Test addresses this unmet medical need by providing answers in only six minutes. Clinicians, in consultation with their patients, can use these results to make real-time adjustments to better manage their patients.
"Mental health professionals have very few tools to aid in patient treatment; as a result, patients are suffering. The MyCare Insite Clozapine Test provides clinicians a first of its kind device. The test is evidence of how Saladax is once again setting new standards for innovation in the treatment and monitoring of patients," said Dr. Salvatore Salamone, CEO and Founder of Saladax Biomedical. "We are changing psychiatry with a single drop of blood.”
ABOUT PSYCHOSIS
Psychosis is a condition that affects the way your brain processes information. It causes you to lose touch with reality. Psychotic disorders, like schizophrenia, involve psychosis that usually affects you for the first time in the late teen years or early adulthood. Young people are especially at risk, but doctors don’t know why.
ABOUT THE MyCARE INSITE CLOZAPINE TEST
The MyCare Insite Clozapine Test is intended for the in vitro quantitative measurement of clozapine in human capillary finger blood using the MyCare Insite.
ABOUT SALADAX
Founded in 2004, Saladax Biomedical, Inc. is a privately held company headquartered as an anchor tenant at Ben Franklin TechVentures® located on Lehigh University’s campus in Bethlehem, PA.
Saladax develops rapid blood tests for point-of-care and for laboratory analysers for use in psychiatry and oncology. The Saladax MyCare Psychiatry line provides drug levels for greater insight into patient adherence and possible causes of treatment failures. These tests enable psychiatrists to more accurately assess adherence and better adjust medication dosing. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2016 certified.
For more information, visit Saladax.com or MyCareTests.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005085/en/
Contact information
Saladax Biomedical, Inc.
Salvatore Salamone, Ph.D., 610-419-6731
ssalamone@saladax.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Former SADA Executive Lusine Yeghiazaryan Joins Picsart as CFO to Drive AI-Native Video Growth Strategy3.9.2026 15:00:00 EEST | Press release
Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today announced the appointment of Lusine Yeghiazaryan as Chief Financial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903569581/en/ Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today announced the appointment of Lusine Yeghiazaryan as Chief Financial Officer. Yeghiazaryan joins Picsart at a pivotal chapter in its evolution, as the company expands beyond its roots as a leading creative platform to build a video-first, AI-powered production ecosystem. Already in motion, Picsart users created over 1.1B AI videos and images since launch, with YTD AI usage up 270% year over year - underscoring the company’s accelerating push to capture a larger share of the fast-growing AI content m
NetApp and AWS Accelerate Storage Migrations with AWS Transform3.9.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Amazon Web Services (AWS) today announced that AWS Transform now supports Amazon FSx for NetApp ONTAP, making it even easier for enterprises to move applications and data to AWS. AWS Transform is an agentic AI service that automates the discovery, planning, and migration of workloads to the cloud. Now generally available, customers can use AWS Transform to migrate attached storage from their on-premises and cloud estates directly to Amazon FSx for ONTAP. “Cloud migration projects often take longer and cost more than expected because customers have to move applications, servers, networking, and storage separately,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage and Services at NetApp. “With AWS Transform and Amazon FSx for NetApp ONTAP, customers can simplify that process, reduce migration risk, and move to AWS faster without changing how their applications operate.” Amazon FSx for Ne
Hitachi Expands HMAX to Accelerate the Deployment of Physical AI3.9.2026 15:00:00 EEST | Press release
Hitachi, Ltd. ("Hitachi") today announced the expansion of HMAX by Hitachi ("HMAX")*, a next-generation suite of solutions that brings the power of AI to social infrastructure. The HMAX portfolio consists of Domain-Specific Solutions tailored to industries and business operations, as well as a set of foundry solutions that span across domains. As part of this expansion, HMAX Data Center has been added as a Domain-Specific Solution for data center operators. Additionally, HMAX Cyber, HMAX Data Fabric, and HMAX AI Operations are being introduced as foundry solutions that support not only Physical AI initiatives within HMAX but also integrate and support enterprises' existing systems across different domains and environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903046122/en/ HMAX Solutions Portfolio Overview Today, social infrastructure operators face growing challenges as the number and complexity of facilities a
MultiBank Group Named Most Regulated Global Financial Derivatives Institution.3.9.2026 14:47:00 EEST | Press release
MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903046526/en/ MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. The award highlights MultiBank Group’s strong global regulatory framework as it holds more than 18 regulatory licences across five continents, including the Australian Securities and Investments Commission (ASIC), the German Federal Financial Supervisory Authority (BaFin), the Cyprus Securities and Exchange Commission (CySEC), the UAE’s Capital Market Authority (CMA), reflecting its longstanding commitment to governance, compliance and transparency. The latest recognition adds to MultiBank Group’s growing award portfolio of more than 80 international industry awards, spanning areas including financial services, trading technology, reg
Humanoids Dominate the Headlines, but Specialized Physical AI Captures Value in $18 Billion Market, Arthur D. Little’s Blue Shift Finds3.9.2026 13:07:00 EEST | Press release
Arthur D. Little’s (ADL) Blue Shift, its forward-looking institute exploring the impact of emerging technologies on business and society, today published I, Robot. Despite the hype around humanoid robots, this report finds they are still immature, compared to other areas of physical AI (autonomous and versatile robots that can perceive, decide, and act in the physical world). ADL analysis shows that humanoid robots only account for $2-3 billion of today’s overall $18 billion physical AI market. Many demonstrations are pre-programmed, remotely operated or even totally AI-generated. The study highlights that specialized physical AI offers the real opportunity for innovation and value in the short-to-medium term, and that businesses should take action now. The overall market could reach $60-$100 billion by 2030, thanks to drivers including labor shortages, shifting work preferences, increasing needs for operational resilience and productivity pressures. Countries and regions are competing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom